 The FDA has cleared Sorrento Therapeutics Incs NASDAQ: SRNE investigational new drug application IND for intravenous IV STI-9167 COVISHIELD to study the safety and pharmacokinetics in healthy volunteers. STI-9167 is the IV formulation of the intranasal STI-. 